+ A

Celltrion to sell 2 biosimilars through export subsidiary

Sept 29,2018
The Korean biopharmaceutical firm Celltrion Inc. said Friday that it has signed a deal with an affiliate to sell two biosimilars - Truxmia and Herzuma.

Under the deal, worth 151.4 billion won ($136.4 million) and equivalent to nearly 16 percent of the company’s annual sales, Celltrion will sell the biosimilars to Celltrion Healthcare, which handles Celltrion’s overseas business.

Truxima will be used in the treatment of diseases including rheumatoid arthritis and non-Hodgkin’s lymphoma, a type of leukemia.

Herzuma is a drug to treat breast cancer.